Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ageless vs EmbraceRX

Ageless
Graded #10

Higher grade

vs+26.199999999999996
EmbraceRX
Graded #362

Lower grade

The verdict

Ageless takes it — 84.8/100 to 58.6/100.

Ageless grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the broadest compounded storefronts on the board — GLP-1, NAD+, sermorelin, TRT and more under one roof, in both injectable and oral routes, on low headline pricing (semaglutide $119/mo, tirzepatide $169/mo) — offset by a compounded-only catalog and an undisclosed state list.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAgeless +45
90
45
Dose & formulationAgeless +34
90
56
Clinical oversightAgeless +4
80
76
Labs & monitoringAgeless +26
78
52
FulfillmentAgeless +11
84
73
Contract termsAgeless +27
82
55
Ageless · left barEmbraceRX · right bar

The numbers

MetricAgelessEmbraceRX
WeighScore84.8/10058.6/100
GradeBC
Scorecard rank#10#362
Semaglutide$119/moNot disclosed
Tirzepatide$169/moNot disclosed
CoverageVaries by stateCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Ageless

Graded #10 · B

Strengths

  • Unusually broad compounded menu — GLP-1, NAD+, sermorelin, TRT, LDN and more, in both injectable and oral formats
  • Low headline GLP-1 pricing — semaglutide $119/mo, tirzepatide $169/mo — no insurance, with Klarna/Affirm financing
  • Fully online: licensed-clinician review and discreet delivery, with upfront compounded/not-FDA disclosures
  • Oral routes available (drops and troches), not injection-only

Where it loses points

  • Everything is compounded and not FDA-approved — not equivalent to brand Wegovy/Ozempic/Zepbound
  • Oral GLP-1 drops and troches lack robust absorption/efficacy evidence versus injectables
  • No published state-availability list and no named legal entity or medical group
  • Thin public track record, and advertised prices are floors set after clinical review
EmbraceRX

Graded #362 · C

Strengths

  • Broad compounded GLP-1 menu — semaglutide (+B12), tirzepatide, oral semaglutide/tirzepatide capsules, plus Lipo-B
  • Large peptide/longevity catalog (BPC-157, GHK-Cu, NAD+, MOTS-C) across injectable, oral, topical, and nasal formats
  • Clinician-guided, compounded at FDA-registered pharmacies; partners with a licensed physician network (Samaritan MD)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, CCPA, Returns & Refunds)

Where it loses points

  • Pricing not shown upfront — revealed only at checkout after a dose selection
  • Offers investigational/research compounds (e.g., retatrutide, AOD-9604) that are not FDA-approved
  • Compounding pharmacy partner not named ('FDA-registered pharmacies')
  • Not LegitScript-certified (no certification displayed)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard